Skip to main content
Feature Story

Cover Story: Overcoming ibrutinib resistance

By Lauren Martz, Staff Writer

Overcoming ibrutinib resistance

Imbruvica ibrutinib's unprecedented response rate in mantle cell lymphoma is generating excitement around the new drug, but as with many targeted cancer therapies, tumors can ultimately become resistant. A recent study from Weill Cornell Medical College suggests that another therapeutic about to hit the market-the cyclin dependent kinase 4 inhibitor palbociclib-could prevent or overcome resistance when used in combination with Imbruvica or a phosphoinositide 3-kinase inhibitor.1

Full Article

Today's Biotech & Pharma News

Profiles Targeted Therapies

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.